Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
Grant helps researchers better study important young-onset Parkinson’s protein
January 25, 2017
Dr.
Michael Schlossmacher
and BioLegend Inc.’s Dr.
Peggy Taylor
were awarded $200,000 USD by The Michael J. Fox Foundation for Parkinson’s Research to create research tools that can identify various forms of a specific brain protein that is involved in about half of young-onset Parkinson’s disease cases. The protein is called Parkin, and it protects adults from an inherited form of Parkinson’s. People who are missing Parkin usually have symptoms starting before age 40. Parkin exists in different forms in the human brain, but researchers currently do not have the tools to identify and investigate these modified forms. Dr. Schlossmacher, Dr. Taylor and their team members plan to develop antibodies that will specifically bind to these different forms of Parkin. These antibodies will help researchers better understand the role Parkin plays in both healthy and diseased brains. They also may help diagnose different subtypes of Parkinson’s disease based on different forms and quantities of Parkin in an individual’s brain. The team plans to distribute the antibodies commercially to other researchers once they are validated.
Additional team members include:
Dr. Brian O’Nuallain of BioLegend, and Jackie Tokarew, Daniel El-Kodsi, and Dr. Julianna Tomlinson in the Schlossmacher lab.